Galmed Pharmaceuticals Ltd. (GLMD) Q3 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the GOMED conference call to discuss financial results for the third quarter 2021. Today's conference is being recorded. Before we begin, please note that we will be making 34 statements on today's call, including those regarding financial results, statements and forecasts regarding anticipated timelines and expectations with respect to our regulatory and clinical development programs, as well as other statements that relate to future events. These statements are based on the beliefs and expectations of management as of today, and actual results, trends, timelines, and projections relating to our financial position and projected development programs and pipeline could differ materially. We urge all investors to read carefully the risks and uncertainties disclosed in our filings with the SEC, including without limitation the risk under the heading risk factors described in our annual report on Form 20-F filed with the SEC. and the risks and uncertainties, including in the form 6-3, filed with the SEC earlier today. GOMID assumes no obligation to update any further statement or information, which speak as of their respective dates only. I would now like to turn the call over to Alan Barra, President and Chief Executive Officer. Alan, please go ahead. Thank you, Shamali. Good morning, and thank you for joining us on today's conference call. I'm pleased to be here today with our Chief Scientific Officer, Dr. Liat Hayar-Deni, and our Chief Financial Officer, Yochai Stensler. We are also grateful to have with us today our guest KOL, Professor Vlad Ratio, from the Sorbonne University and RMO Study Co-Principal Investigator. Professor Ratio will present the results from the first dataset of the open-label part of our Phase III RMO Study also referred ...